Belzutifan VHL RCC HK Prospective Registry
A Prospective Registry for Belzutifan in the Treatment of Von Hippel-Lindau (VHL) Disease
Sponsor: Chinese University of Hong Kong
A observational or N/A phase clinical study on VHL - Von Hippel-Lindau Syndrome, this trial is actively recruiting participants. The trial is conducted by Chinese University of Hong Kong and has accumulated 1 data snapshot since 2026. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Study Description(click to expand)Adult patients diagnosed with VHL syndrome who choose to use belzutifan for their treatment will be identified and invited to participate in this registry. Clinical data, laboratory tests, imaging results and QOLs will be collected from subjects at baseline, every 3 months for the first year, then every 6 months until month 36 or cessation of the medication, whichever occurs first.
Adult patients diagnosed with VHL syndrome who choose to use belzutifan for their treatment will be identified and invited to participate in this registry. Clinical data, laboratory tests, imaging results and QOLs will be collected from subjects at baseline, every 3 months for the first year, then every 6 months until month 36 or cessation of the medication, whichever occurs first.
Status Flow
Change History
1 version recordedEligibility Summary
This study aims to evaluate the Belzutifan's efficacy, drug safety, disease course, and the health-economic impact of the treatment to Von Hippel-Lindau (VHL) syndrome.
Contact Information
- Chinese University of Hong Kong
For direct contact, visit the study record on ClinicalTrials.gov .